# A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

> **NCT05811351** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 305 (actual)

## Conditions studied

- Geographic Atrophy

## Interventions

- **DRUG:** JNJ-81201887
- **DRUG:** Prednisone
- **OTHER:** Placebo
- **DRUG:** Triamcinolone
- **OTHER:** Sham Procedure

## Key facts

- **NCT ID:** NCT05811351
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-06
- **Primary completion:** 2026-02-23
- **Final completion:** 2026-02-23
- **Target enrollment:** 305 (ACTUAL)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05811351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05811351, "A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05811351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*